Inmune Bio earnings were -$42.1M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest INMB earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$9.2M, down 23.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, INMB reported annual earnings of -$42.1M, with 40.2% growth.
On INMB's earnings call on Invalid Date, Inmune Bio (NASDAQ: INMB) reported Q4 2024 earnings per share (EPS) of -$0.40, up 14.89% year over year. Total INMB earnings for the quarter were -$9.22 million. In the same quarter last year, Inmune Bio's earnings per share (EPS) was -$0.47.
As of the last Inmune Bio earnings report, Inmune Bio is currently losing money. Inmune Bio's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$42.08 million, a 40.24% increase year over year.
What was INMB's earnings growth in the past year?
As of Inmune Bio's earnings date in Invalid Date, Inmune Bio's earnings has grown year over year. INMB earnings in the past year totalled -$42.08 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.